Sign In
Buy HROW
$33.32
+0.460 (+1.40%)
At Close: Jun 03, 2026
Harrow Announces Closing of Acquisition of Melt Pharmaceuticals
07:00am, Tuesday, 18'th Nov 2025
NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acq
Private Capital's Strategic Moves: Spotlight on Matthews International Corp
05:03pm, Friday, 14'th Nov 2025
Insights from Private Capital (Trades, Portfolio)'s Third Quarter 2025 13F Filing Private Capital (Trades, Portfolio) recently submitted its 13F filing for the
Harrow, Inc. (HROW) Q3 2025 Earnings Call Transcript
02:11pm, Tuesday, 11'th Nov 2025
Harrow, Inc. ( HROW ) Q3 2025 Earnings Call November 11, 2025 8:00 AM EST Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO & Chairman of the B
Harrow Announces Third Quarter 2025 Financial Results
04:05pm, Monday, 10'th Nov 2025
Third-Quarter 2025 and Recent Selected Highlights: Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year period GAAP net income of $1.0 million Adjusted EBITD
Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential
12:31pm, Wednesday, 05'th Nov 2025
Harrow, Inc. is an ophthalmology company with strong revenue growth, ambitious targets, and a diverse product portfolio including Vevye and Iheezo. HROW targets $280M in 2025 revenue and >$250M per qu
Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025
07:00am, Monday, 27'th Oct 2025
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 11, 2025 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 11, 2025
Harrow: Positive And Negative Adjustments After Investor Day Offset Each Other
09:03pm, Wednesday, 15'th Oct 2025
Harrow's recent debt refinancing, Melt Pharmaceuticals acquisition plans, and updated peak sales estimates reinforce the bullish thesis. Base case DCF modeling projects significant revenue growth thro
ImprimisRx Announces Leadership Changes
07:00am, Monday, 06'th Oct 2025
Frank Mullery Appointed Chief Executive Officer of ImprimisRx Bridseida Cruz Appointed Head of Quality of ImprimisRx NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leadin
Harrow, Inc. (HROW) Analyst/Investor Day Transcript
12:27am, Saturday, 27'th Sep 2025
Harrow, Inc. (NASDAQ:HROW ) Analyst/Investor Day September 26, 2025 11:30 AM EDT Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO & Chairman o
Harrow to Acquire Melt Pharmaceuticals
07:00am, Friday, 26'th Sep 2025
NASHVILLE, Tenn., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into
Harrow Launches Harrow Access for All (HAFA)
04:05pm, Thursday, 25'th Sep 2025
HAFA to Expand Harrow's Innovative Market Access Model Across Ophthalmic Portfolio Program will be available in late 2025 through the HarrowAccess.com Portal NASHVILLE, Tenn., Sept. 25, 2025 (GLOBE NE
Harrow Announces Agenda and Speakers for Investor & Analyst Day
07:00am, Monday, 15'th Sep 2025
NASHVILLE, Tenn., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the agenda for its upcomi
Harrow: Buy A Blend Of Value And Growth
10:57am, Friday, 12'th Sep 2025
I'm bullish on Harrow due to the VEVYE Access for All program, which makes dry eye treatment affordable and drives strong prescription growth. VEVYE's discounted pricing addresses a massive, undertrea
Harrow: A Classical GARP Stock
01:11pm, Tuesday, 09'th Sep 2025
Harrow's focused acquisition model in ophthalmic drugs enables high growth, with a diversified portfolio and limited R&D expenses. My DCF analysis suggests a fair value of $72.75 per share—nearly 10
Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030
05:57pm, Monday, 08'th Sep 2025
NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its privat
